Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by equities researchers at Cowen in a research report issued to clients and investors on Wednesday. They currently have a $450.00 target price on the biopharmaceutical company’s stock. Cowen’s price objective indicates a potential upside of 34.48% from the company’s previous close.
Other analysts also recently issued reports about the company. BTIG Research restated a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. Canaccord Genuity restated a “buy” rating and issued a $522.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday. BMO Capital Markets set a $444.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, November 27th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $480.00 to $380.00 in a report on Friday, December 1st. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $470.84.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $4.19 during midday trading on Wednesday, reaching $334.61. The company had a trading volume of 985,317 shares, compared to its average volume of 978,731. The firm has a market capitalization of $36,010.00, a P/E ratio of 30.39, a price-to-earnings-growth ratio of 1.25 and a beta of 1.47. Regeneron Pharmaceuticals has a 1-year low of $319.50 and a 1-year high of $543.55. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.